Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hallgeir Rui

Showing results (71-80 of 138) with videos related to

Pageof 14
Sort By:
Cancers|April 23, 2020
Acquired Immunity Is Not Essential for Radiation-Induced Heart Dysfunction but Exerts a Complex Impact on InjuryRachel A Schlaak, Anne Frei, Brian L Fish, et al.
The Journal of Investigative Dermatology|July 3, 2016
Therapeutic Elimination of the Type 1 Interferon Receptor for Treating Psoriatic Skin InflammationJun Gui, Michael Gober, Xiaoping Yang, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 19, 2018
Control of CCND1 ubiquitylation by the catalytic SAGA subunit USP22 is essential for cell cycle progression through G1 in cancer cellsVictoria J Gennaro, Timothy J Stanek, Amy R Peck, et al.
Annals of Surgery|August 27, 2010
HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patientsNathan G Richards, David W Rittenhouse, Boris Freydin, et al.
Endocrinology|March 18, 2021
Leveraging Antiprogestins in the Treatment of Metastatic Breast CancerSailaja Kamaraju, Amy M Fowler, Elizabeth Weil, et al.
BMC Cancer|June 30, 2016
Erratum to: The effect of soluble E-selectin on tumor progression and metastasisShin-Ae Kang, Celine A Blache, Sandra Bajana, et al.
BMC Cancer|May 26, 2016
The effect of soluble E-selectin on tumor progression and metastasisShin-Ae Kang, Celine A Blache, Sandra Bajana, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 18, 2016
Validation of tumor protein marker quantification by two independent automated immunofluorescence image analysis platformsAmy R Peck, Melanie A Girondo, Chengbao Liu, et al.
Breast Cancer Research : BCR|June 17, 2019
The p52 isoform of SHC1 is a key driver of breast cancer initiationKevin D Wright, Bradley S Miller, Sarah El-Meanawy, et al.
Cancer Research|July 17, 2009
The cell fate determination factor DACH1 is expressed in estrogen receptor-alpha-positive breast cancer and represses estrogen receptor-alpha signalingVladimir M Popov, Jie Zhou, L Andrew Shirley, et al.
Pageof 14

Showing results (71-80 of 138) with videos related to

Sort By:
Pageof 14
Cancers|April 23, 2020
Acquired Immunity Is Not Essential for Radiation-Induced Heart Dysfunction but Exerts a Complex Impact on InjuryRachel A Schlaak, Anne Frei, Brian L Fish, et al.
The Journal of Investigative Dermatology|July 3, 2016
Therapeutic Elimination of the Type 1 Interferon Receptor for Treating Psoriatic Skin InflammationJun Gui, Michael Gober, Xiaoping Yang, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 19, 2018
Control of CCND1 ubiquitylation by the catalytic SAGA subunit USP22 is essential for cell cycle progression through G1 in cancer cellsVictoria J Gennaro, Timothy J Stanek, Amy R Peck, et al.
Annals of Surgery|August 27, 2010
HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patientsNathan G Richards, David W Rittenhouse, Boris Freydin, et al.
Endocrinology|March 18, 2021
Leveraging Antiprogestins in the Treatment of Metastatic Breast CancerSailaja Kamaraju, Amy M Fowler, Elizabeth Weil, et al.
BMC Cancer|June 30, 2016
Erratum to: The effect of soluble E-selectin on tumor progression and metastasisShin-Ae Kang, Celine A Blache, Sandra Bajana, et al.
BMC Cancer|May 26, 2016
The effect of soluble E-selectin on tumor progression and metastasisShin-Ae Kang, Celine A Blache, Sandra Bajana, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 18, 2016
Validation of tumor protein marker quantification by two independent automated immunofluorescence image analysis platformsAmy R Peck, Melanie A Girondo, Chengbao Liu, et al.
Breast Cancer Research : BCR|June 17, 2019
The p52 isoform of SHC1 is a key driver of breast cancer initiationKevin D Wright, Bradley S Miller, Sarah El-Meanawy, et al.
Cancer Research|July 17, 2009
The cell fate determination factor DACH1 is expressed in estrogen receptor-alpha-positive breast cancer and represses estrogen receptor-alpha signalingVladimir M Popov, Jie Zhou, L Andrew Shirley, et al.
Pageof 14